nach oben

Journal of Clinical Immunology

Erschienen in:

01.09.2009

Differential Transcriptional Expression of PPARα, PPARγ1, and PPARγ2 in the Peritoneal Macrophages and T-cell Subsets of Non-obese Diabetic Mice

verfasst von: Nik-Soriani Yaacob, Mohd Arifin Kaderi, Mohd-Nor Norazmi

Erschienen in: Journal of Clinical Immunology | Ausgabe 5/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

The peroxisome proliferator-activated receptors (PPARs) have been implicated in immune regulation. We determined the transcriptional expression of the three isoforms, PPARα, PPARγ1, and PPARγ2 in the peritoneal macrophages, CD4- and CD8-positive lymphocytes in non-obese diabetic (NOD) mice at 5 and 10 weeks of age as well as at diabetic stage.

Results

Compared to the non-obese diabetic resistant (NOR) mice, the peritoneal macrophages of NOD mice expressed increased levels of PPARα but reduced levels of PPARγ2, while PPARγ1 expression was unchanged in all age groups. CD4-positive lymphocytes expressed low levels of PPARα in diabetic NOD mice and greatly reduced expression of PPARγ2 in all age groups. Unlike peritoneal macrophages and CD4-positive cells, the CD8-positive cells expressed low levels of PPARγ1 in diabetic NOD mice but no difference in PPARα and PPARγ2 expression was observed compared to NOR mice.

Conclusion

The current findings may suggest an important regulatory role of PPARs in the pathogenesis of autoimmune diabetes.

Hutchings P, Rosen H, O’Reilly L, Simpson E, Gordon S, Cooke A. Transfer of diabetes in mice prevented by blockage of adhesion-promoting receptors on macrophages. Nature. 1990;348:639–42. doi:10.1038/348639a0.PubMedCrossRef

Bendelac A, Carnaud C, Boitard C, Bach JF. Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Lyt-2+ T cells. J Exp Med. 1987;166:823–32. doi:10.1084/jem.166.4.823.PubMedCrossRef

Yaacob NS, Kaderi MA, Norazmi MN. The expression of cytokine genes in the peritoneal macrophages and splenic CD4- and CD8-positive lymphocytes of the non-obese diabetic mice. J Clin Immunol. 2004;24:177–84. doi:10.1023/B:JOCI.0000019783.61674.1d.PubMedCrossRef

Rabinovitch A. Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM. Therapeutic intervention by immunostimulation? Diabetes. 1994;43:613–21. doi:10.2337/diabetes.43.5.613.PubMedCrossRef

Isseman I, Green S. Activation of a number of the steroid receptor superfamily by peroxisome proliferators. Nature. 1990;347:645–50. doi:10.1038/347645a0.CrossRef

Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A. 1994;91:7355–9. doi:10.1073/pnas.91.15.7355.PubMedCrossRef

Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta and -gamma in the adult rat. Endocrinology. 1996;137:354–66. doi:10.1210/en.137.1.354.PubMedCrossRef

Vidal-Puig AJ, Considine RV, Jimenez-Linan M, Werman A, Pories WJ, Caro JF, et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest. 1997;99:2416–22. doi:10.1172/JCI119424.PubMedCrossRef

Lampen A, Carlberg C, Nau H. Peroxisome proliferator-activated receptor delta is a specific sensor for teratogenic valproic acid derivatives. Eur J Pharmacol. 2001;431:25–33. doi:10.1016/S0014-2999(01)01423-6.PubMedCrossRef

10.

Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell. 1994;79:1147–56. doi:10.1016/0092-8674(94)90006-X.PubMedCrossRef

11.

Zhu Y, Qi C, Korenberg JR, Chen XN, Noya D, Rao MS, et al. Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms. Proc Natl Acad Sci U S A. 1995;92:7921–5. doi:10.1073/pnas.92.17.7921.PubMedCrossRef

12.

Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, et al. International Union of Pharmacology LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev. 2006;58:726–41. doi:10.1124/pr.58.4.5.PubMedCrossRef

13.

Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol. 2002;2:748–59. doi:10.1038/nri912.PubMedCrossRef

14.

Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82–6. doi:10.1038/35154.PubMedCrossRef

15.

Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391:79–82. doi:10.1038/34178.PubMedCrossRef

16.

Yang XY, Wang LH, Chen T, Hodge DR, Resau JH, DaSilva L, et al. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J Biol Chem. 2000;275:4541–4. doi:10.1074/jbc.275.7.4541.PubMedCrossRef

17.

Augstein P, Dunger A, Heinke P, Wachlin G, Berg S, Hehmke B, et al. Prevention of autoimmune diabetes in NOD mice by troglitazone is associated with modulation of ICAM-1 expression on pancreatic islet cells and IFNg expression in splenic T cells. Biochem Biophys Res Commun. 2003;304:378–84. doi:10.1016/S0006-291X(03)00590-4.PubMedCrossRef

18.

Awara WM, El-Sisi AE, El-Refaei M, El-Naa MM, El-Desoky K. Insulinotropic and anti-inflammatory effects of rosiglitazone in experimental autoimmune diabetes. Rev Diabet Stud. 2005;2:146–56. doi:10.1900/RDS.2005.2.146.PubMedCrossRef

19.

Reddy S, Liu W, Elliott RB. Distribution of pancreatic macrophages preceding and during early insulitis in young NOD mice. Pancreas. 1993;8:602–8. doi:10.1097/00006676-199309000-00012.PubMedCrossRef

20.

Pozzilli P, Signore A, Williams AJ, Beales PE. NOD mouse colonies around the world—recent facts and figures. Immunol Today. 1993;14:193–6. doi:10.1016/0167-5699(93)90160-M.PubMedCrossRef

21.

Clark RB, Bishop-Bailey D, Estrada-Hernandez T, Hla T, Puddington L, Padula SJ. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol. 2000;164:1364–71.PubMed

22.

Yoon JW, Jun HS, Santamaria P. Cellular and molecular mechanisms for the initiation and progression of beta cell destruction resulting from the collaboration between macrophages and T cells. Autoimmunity. 1998;27:109–22. doi:10.3109/08916939809008041.PubMedCrossRef

23.

McDuffie M, Maybee NA, Keller SR, Stevens BK, Garmey JC, Morris MA, et al. Nonobese diabetic (NOD) mice congenic for a targeted deletion of 12/15-lipoxygenase are protective from autoimmune diabetes. Diabetes. 2008;57:199–208. doi:10.2337/db07-0830.PubMedCrossRef

24.

Middleton MK, Rubinstein T, Pure E. Cellular and molecular mechanisms of the selective regulation of IL-12 production by 12/15-lipoxygenase. J Immunol. 2006;176:265–74.PubMed

25.

Yu Z, Scheider C, Boeglin WE, Brash AR. Epidermal lipoxygenase products of the hepoxilin pathway selectively activate the nuclear receptor PPARα. Lipids. 2007;42:491–7. doi:10.1007/s11745-007-3054-4.PubMedCrossRef

26.

Tontonoz P, Nagy L, Alvarez JGA, Thomazy VA, Evans RM. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 1998;93:241–52. doi:10.1016/S0092-8674(00)81575-5.PubMedCrossRef

27.

Li M, Pascual G, Glass CK. Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene. Mol Cell Biol. 2000;20:4699–707. doi:10.1128/MCB.20.13.4699-4707.2000.PubMedCrossRef

28.

Cunard R, Ricote M, DiCampli D, Archer DC, Kahn DA, Glass CK, et al. Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. J Immunol. 2002;168:2795–802.PubMed

29.

Jones DC, Ding X, Daynes RA. Nuclear receptor peroxisome proliferator-activated receptor α (PPARα) is expressed in resting murine lymphocytes. The PPARα in T and B lymphocytes is both transactivation and transrepressioncompetent. J Biol Chem. 2002;277:6838–45. doi:10.1074/jbc.M106908200.PubMedCrossRef

30.

Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell. 1992;68:879–87. doi:10.1016/0092-8674(92)90031-7.PubMedCrossRef

31.

Marx N, Kehrle B, Kohlhammer K, Grüb M, Koenig W, Hombach V, et al. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res. 2002;90:703–10. doi:10.1161/01.RES.0000014225.20727.8F.PubMedCrossRef

32.

Wang P, Anderson PO, Chen S, Paulsson KM, Sjogren HO, Li S. Inhibition of the transcription factors AP-1 and NF-kappaB in CD4 T cells by peroxisome proliferator-activated receptor gamma ligands. Int Immunopharmacol. 2001;1:803–12. doi:10.1016/S1567-5769(01)00015-7.PubMedCrossRef

33.

Saubermann LJ, Nakajima A, Wada K, Zhao S, Terauchi Y, Kadowaki T, et al. Peroxisome proliferator-activated receptor gamma agonist ligands stimulate Th2 cytokine response and prevent acute colitis. Inflamm Bowel Dis. 2002;8:330–9. doi:10.1097/00054725-200209000-00004.PubMedCrossRef

34.

Yoshida K, Kikutani H. Genetic and immunological basis of autoimmune diabetes in the NOD mouse. Rev Immunogenet. 2000;2:140–6.PubMed

Titel: Differential Transcriptional Expression of PPARα, PPARγ1, and PPARγ2 in the Peritoneal Macrophages and T-cell Subsets of Non-obese Diabetic Mice
verfasst von: Nik-Soriani Yaacob
Mohd Arifin Kaderi
Mohd-Nor Norazmi
Publikationsdatum: 01.09.2009
Verlag: Springer US
Erschienen in: Journal of Clinical Immunology / Ausgabe 5/2009
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-009-9300-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Differential Transcriptional Expression of PPARα, PPARγ1, and PPARγ2 in the Peritoneal Macrophages and T-cell Subsets of Non-obese Diabetic Mice

Abstract

Background

Results

Conclusion

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin

Springer Medizin

Abstract

Background

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2009

Clinico-immunologic Study on Immunotherapy with Mixed and Single Insect Allergens

High-Dose Dexamethasone Inhibits BAFF Expression in Patients with Immune Thrombocytopenia

Increases in Serum TARC/CCL17 Levels Are Associated with Progression-Free Survival in Advanced Melanoma Patients in Response to Dendritic Cell-Based Immunotherapy

Sequential Changes in Serum Cytokines Reflect Viral RNA Kinetics in Target Organs of a Coxsackievirus B Infection in Mice

Local and Systemic Activation of the Mononuclear Phagocyte System in Aseptic Loosening of Total Hip Arthroplasty

Osteoimmunology: Crosstalk Between the Immune and Bone Systems

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin